Stents Market Size & Share 2026-2035

Stents Market Size

The global stents market was valued at USD 10.1 billion in 2025. The market is expected to reach from USD 10.8 billion in 2026 to USD 22.3 billion in 2035, growing at a CAGR of 8.4% during the forecast period, according to the latest report published by Global Market Insights Inc.

The high market growth is attributed to rising cardiovascular disease prevalence, technological advancements in stent design, an increase in the number of minimally invasive procedures, and expanding healthcare infrastructure in emerging markets, among other factors.
 

Stents are small, tube-shaped medical devices used to maintain the openness of constricted or blocked blood vessels. It promotes regular blood flow and prevents vessels from collapsing. Stents are frequently used for peripheral, coronary, and other vascular procedures.
 

The leading companies in the global stent market are B. Braun, Medtronic, Terumo, Abbott, and Boston Scientific. These companies maintain their competitive edge through significant R&D expenditures, global market presence, and ongoing product innovation.
 

The market has increased from USD 8.1 billion in 2022 and reached USD 9.8 billion in 2024, with the historic growth rate of 10%. The market growth was driven by rising prevalence of cardiovascular diseases, growing geriatric population, and adoption of advanced stent technologies like drug-eluting and bioresorbable stents.
 

As populations age and lifestyle factors such as sedentary habits, unhealthy diets, and smoking continue to rise, the demand for stenting procedures has increased significantly. This growth is primarily driven by the rising incidence of cardiovascular diseases (CVDs), including coronary artery disease, peripheral artery disease, and aneurysms. For instance, according to the World Health Organization (WHO), cardiovascular diseases accounted for approximately 17.9 million deaths globally in 2022, representing 32% of total global deaths.
 

Additionally, the Centers for Disease Control and Prevention (CDC) reported that in the U.S. alone, nearly 697,000 people died from heart disease in 2022, further underscoring the growing need for stenting procedures.
 

Furthermore, advances such as drug-eluting stents, bioresorbable stents, and biodegradable polymer coatings improve safety, reduce restenosis, and improve patient outcomes. These advanced features encourage clinicians to choose newer stent options, thereby driving market growth.

Stents Market Trends

The stents industry is growing considerably with the rise of drug-eluting and bioresorbable stents, personalized and patient-centric stent solutions, and integration of digital health and smart stents, among other factors collectively driving industry growth.
 

• Drug-eluting stents (DES), which release medication to prevent restenosis, are gradually replacing bare-metal stents (BMS). Furthermore, bioresorbable stents that gradually dissolve inside the artery are gaining popularity, providing long-term vessel healing and lowering complications. This trend reflects the market's preference for safer, more patient-friendly solutions.
   
• Manufacturers are focusing on tailoring stent size, design, and material to each patient's unique anatomy and condition. Advanced imaging and AI-assisted planning tools enable precise placement while lowering procedural risks. This trend improves clinical outcomes and increases adoption among cardiologists.
   
• Further, there is increasing research into biodegradable polymer coatings that reduce inflammation, thrombosis, and long-term complications. Next-generation coatings and surface modifications aim to improve biocompatibility and reduce adverse events, signaling a trend toward safer, long-lasting stent technologies, thereby sustaining market growth.
   

Stents Market Analysis

Based on product, the stents market is segmented into vascular stents and non-vascular stents. The vascular stents segment has asserted its dominance in the market by securing a significant market share of 93% in 2025 owing to the high prevalence of coronary artery diseases and widespread adoption of minimally invasive cardiovascular interventions. The segment is expected to exceed USD 21.2 billion by 2035, growing at a CAGR of 8.6% during the forecast period.
 

• Endovascular stenting is preferred over open surgical bypass because it allows for a faster recovery, lowers the risk of complications, and requires fewer hospital stays. Clinicians are increasingly recommending this minimally invasive procedure, which is boosting the use of vascular stents.
   
• Vascular stent adoption is supported by the expansion of cardiovascular care facilities, improved availability of interventional cardiology centers, and increased access to trained specialists in Asia-Pacific, Latin America, and the Middle East. Growing awareness of early detection also contributes to increased procedure rates.
   
• The non-vascular stents segment held a revenue of USD 705.5 million in 2025, with projections indicating a steady expansion at 4.8% CAGR from 2026 to 2035. The rising incidence of gastrointestinal, urological, and respiratory obstructions, combined with advances in stent materials and design for non-vascular applications, is driving market demand.
   

Based on material, the stents market is segmented into metal and polymer. The metal segment dominated the market in 2025, accounting for USD 7.9 billion and is anticipated to grow at a CAGR of 7.8% during the forecast period.
 

• Metal stents, typically made from stainless steel or cobalt-chromium alloys, provide excellent radial strength to keep arteries open. This ensures long-term vessel patency, making them a preferred choice for complex or heavily calcified lesions where durability is critical.
   
• These stents have been used for decades, and their long-term outcomes are well-documented. Physicians’ familiarity and confidence in metal stents drive their continued use, especially in regions where advanced bioresorbable options are less accessible.
   
• The polymer segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 10.3% over the forecast period. Rising preference for bioresorbable polymer stents due to reduced long-term complications and improved patient safety is boosting adoption in cardiovascular and non-vascular procedures.
   

Based on type, the stents market is segmented into balloon expandable and self expandable. The balloon expandable segment dominated the market in 2025, accounting for USD 6.3 billion and is anticipated to grow at a CAGR of 7.9% during the forecast period.
 

• A balloon catheter is used to deploy balloon-expandable stents, enabling accurate implantation at the targeted lesion. They are the recommended choice for coronary interventions because of their accuracy, which lowers the chance of misalignment, especially in complex or calcified arteries.
   
• These stents exert significant radial force to keep the artery open following expansion, preventing vessel collapse or recoil. Their durability is especially useful in treating tight stenotic lesions or areas subjected to high mechanical stress.
   
• The self expandable segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 9.3% over the forecast period. The growing use in complex vascular and non-vascular anatomies, as well as their ability to conform to tortuous vessels and provide long-term patency, is driving market growth.

Based on end use, the stents market is classified into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 73.6% in 2025 and is expected to reach USD 16 billion within the forecast period.
 

• Hospitals are increasingly adopting percutaneous coronary interventions (PCI) and endovascular procedures over open surgeries. Stent implantation reduces patient recovery time, shortens hospital stays, and lowers procedural risks, aligning with hospitals’ goals of improving patient throughput and outcomes.
   
• Hospitals are witnessing growing admissions for coronary artery disease, peripheral artery disease, and other vascular conditions due to aging populations and lifestyle-related risk factors. This rising patient volume drives higher demand for stents across cardiac and peripheral interventions.
   
• The ambulatory surgical centers segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 9.1% over the forecast period. The rise of outpatient cardiac procedures and cost-effective minimally invasive interventions is increasing stent procedures in ambulatory surgical centers. Enhanced patient convenience and shorter recovery times further support market adoption in these settings.

North America Stents Market

North America dominated the market with the highest market share of 36.9% in 2025.
 

• The U.S. stents industry was valued at USD 2.9 billion and USD 3.1 billion in 2022 and 2023, respectively. The market size reached USD 3.5 billion in 2025, growing from USD 3.4 billion in 2024, and is anticipated to grow at a CAGR of 7.4% between 2026 to 2035.
   
• The rising prevalence of coronary artery disease (CAD) and peripheral artery disease (PAD) in the U.S. and Canada is increasing demand for stents. The aging population, as well as lifestyle risk factors like obesity, hypertension, and diabetes, contribute to increased procedural volume. Hospitals are increasingly using minimally invasive interventions, preferring stents over open surgeries.
   
• Further, the presence of cutting-edge hospitals, specialized cardiac centers, and catheterization labs facilitates high-volume stent procedures. Insurance coverage and reimbursement policies in the U.S. and Canada lower out-of-pocket expenses, encouraging both elective and emergency treatments.
   
• Hospitals now have robotic-assisted stent deployment systems, which improves procedural efficiency. Telemedicine and remote monitoring integration can also help with post-stent care, increasing patient compliance and follow-ups.
   

Europe Stents Market

Europe stents industry accounted for USD 3 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• European countries, especially Germany, France, and the U.K., provide structured reimbursement and insurance coverage for stent implantation. National health systems encourage minimally invasive treatments to reduce hospital stays. This reduces financial barriers, encouraging patients to opt for advanced stents.
   
• Increasing rates of obesity, diabetes, and sedentary lifestyles in Western Europe escalate CVD prevalence. This creates a continuous pool of patients requiring coronary and peripheral stent interventions. Urban populations, in particular, contribute to higher procedural volumes.
   

Asia Pacific Stents Market

The Asia Pacific stents industry is anticipated to grow at the highest CAGR of 9.8% during the analysis timeframe.
 

• Countries like China and India are witnessing a sharp rise in CVD incidence due to urbanization, lifestyle changes, and aging populations. This creates a large patient pool for stent procedures. Early diagnosis is improving due to better hospital infrastructure in tier-1 cities.
   
• Increasing patient awareness of minimally invasive treatments, combined with government subsidies and private insurance expansion, drives stent adoption. Patients in urban areas increasingly prefer stent procedures over traditional surgeries.
   

Latin America Stents Market

The Latin America stents industry is experiencing robust growth over the analysis timeframe.
 

• Investment in public hospitals and private cardiac centers enables better stent availability. Reimbursement policies and insurance schemes in Brazil, Argentina, and Chile reduce out-of-pocket expenses for patients.
   
• Awareness campaigns for heart health and minimally invasive procedures encourage patients to opt for stents. Urban patients increasingly prefer stent implantation over traditional surgery for shorter recovery times.
   
• Some Latin American countries attract regional patients for affordable stent procedures. The combination of cost-effectiveness and quality care boosts demand for advanced stents.
   

Middle East & Africa Stents Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.
 

• GCC countries are investing heavily in healthcare infrastructure, including specialized cardiac centers. Public hospitals and private sector investments improve procedural capacity for stent implantation.
   
• Hospitals in MEA are adopting drug-eluting stents, bioresorbable scaffolds, and hybrid stent systems. Partnerships with multinational manufacturers improve access to advanced stents.
   

Stents Market Share

The stents industry is highly competitive and dominated by a mix of multinational corporations and emerging regional players. The market is characterized by intense innovation in drug-eluting stents (DES), bioresorbable scaffolds, and peripheral stents, with companies investing heavily in R&D to improve clinical outcomes, reduce restenosis rates, and enhance procedural efficiency.
 

Strategic collaborations, mergers, and acquisitions are common, allowing companies to expand their geographical footprint and product portfolios. Emerging players, especially in Asia Pacific and Latin America, are leveraging cost-effective manufacturing and local partnerships to capture market share, intensifying competition further.
 

Key players include Abbott, Boston Scientific, Medtronic, Terumo, and B. Braun, collectively accounting for ~60% of the total market share. These companies maintain dominance through strong brand recognition, extensive distribution networks, and continuous product innovation. Smaller regional manufacturers compete on pricing and niche applications, often targeting underserved markets with customized stent solutions. Regulatory approvals, clinical trial successes, and physician preference play a critical role in shaping competitive positioning, while technological advancements such as next-generation DES and biodegradable stents drive differentiation.
 

Overall, the competitive landscape is dynamic, with multinational giants focusing on advanced technologies and market expansion, while regional and emerging players target affordability and accessibility. Rapid innovations, coupled with growing CVD prevalence and healthcare infrastructure development, ensure that competition remains fierce, pushing companies to continually upgrade product offerings and expand into new regions to sustain growth.
 

Stents Market Companies

Few of the prominent players operating in the stents industry include:

• Abbott
• B. Braun
• Becton, Dickinson and Company
• Biosensors International Group
• Biotronik
• Boston Scientific
• Elixir Medical
• Medtronic
• Meril Life Science
• MicroPort Scientific
• SLTL Group
• Stryker
• Terumo
• Veryan Medical
• W.L Gore & Associates
   

• Abbott

It offers a comprehensive portfolio of drug-eluting and bioresorbable stents with proven low restenosis rates, backed by extensive clinical trial data. Known for innovative delivery systems that enhance precision and procedural efficiency.
 

• Boston Scientific

It focuses on advanced drug-eluting and specialty stents for complex coronary and peripheral cases, emphasizing long-term patient outcomes. Strong global distribution and physician training programs support high adoption rates.
 

• Medtronic

Provides a broad range of coronary and peripheral stents with cutting-edge technologies, including durable polymer and biodegradable options. Known for reliability, procedural safety, and integration with imaging guidance systems for optimal placement.
 

Stents Industry News:

• In July 2025, InspireMD, Inc. announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., designed to minimize both early and late embolism risk by trapping potential emboli against the arterial wall while preserving external carotid artery perfusion. The system offered interventional specialists a safer option for carotid artery procedures, improving clinical outcomes. This launch is expected to expand InspireMD’s presence in the U.S. market.
   
• In May 2024, Abbott announced the launch of the XIENCE Sierra Everolimus Eluting Coronary Stent System in India, marking the availability of one of the latest-generation stents in the XIENCE family for patients with blocked coronary arteries. The stent offered interventional cardiologists enhanced safety for complex cases and advanced procedural outcomes. This launch strengthened Abbott’s market presence in India and contributed to growth in the coronary stents segment by increasing access to next-generation stent technology.
   
• In May 2022, Medtronic received the U.S. FDA approval for its Onyx frontier drug eluting stent indicated for coronary artery disease in patients with plaque buildup inside the coronary arteries. This launch enabled the company to expand its product portfolio and increase its customer base, thus driving the revenue growth.
   

The stents market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Market, By Product

• Vascular stents
  • Coronary stents
    • Drug eluting stent
    • Bioresorbable vascular scaffold (BVS)
    • Bare metal stent
  • Peripheral stents
    • Renal
    • Iliac
    • Femoral-popliteal
    • Carotid
  • Neurovascular stents
• Non-vascular stents

Market, By Material

• Metal
• Polymer

Market, By Type

• Balloon expandable
• Self expandable

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users
   

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE